Clinical and Applied Thrombosis/Hemostasis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to start reading!

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deliargyris, E. N.
Right arrow Articles by Sane, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deliargyris, E. N.
Right arrow Articles by Sane, D. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4, 458-464 (2006)
DOI: 10.1177/1076029606293432

Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab but not Eptifibatide During PCI

Efthymios N. Deliargyris, MD

Wake Forest University School of Medicine, Winston-Salem, NC

Bharathi Upadhya, MD

Wake Forest University School of Medicine, Winston-Salem, NC

Laura G. Melton, PhD

University of North Carolina School of Medicine, Chapel Hill, NC

Cheryl Thompson, BS

University of North Carolina School of Medicine, Chapel Hill, NC

Melrose Fisher, RN

University of North Carolina School of Medicine, Chapel Hill, NC

Don A. Gabriel, MD, PhD

University of North Carolina School of Medicine, Chapel Hill, NC

Gregory J. Dehmer, MD

Scott & White Clinic, Texas A&M School of Medicine, Temple, TX

David C. Sane, MD

Wake Forest University School of Medicine, Winston-Salem, NC, dsane{at}wfubmc.edu

In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p<0.001 for both) and after UFH (95% [93-100] vs. 79% [68.8-87.5] [ADP]; 82% [77-93] vs. 51% [34.5-71.3] [TRAP], p<0.001 for both). Addition of UFH significantly reduced platelet inhibition in the abciximab group (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP], p<0.05 for both) but not in the eptifibatide group (96.5% [94-100] vs. 95% [93-100] [ADP]; 89.5% [84-95] vs. 82% [77-93] [TRAP], p=ns for both). Eptifibatide achieved superior platelet inhibition before but especially after UFH compared with abciximab.

Key Words: Heparin • Platelets • Abciximab • Eptifibatide • Platelet aggregation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
V. Katsaridis, C. Papagiannaki, N. Skoulios, I. Achoulias, and D. Peios
Local Intra-Arterial Eptifibatide for Intraoperative Vessel Thrombosis during Aneurysm Coiling
AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1414 - 1417.
[Abstract] [Full Text] [PDF]